Novartis sells off blood diagnostics division


Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion (£1 billion). The sale will allow the company to ‘focus more sharply on [its] strategic businesses’, according to chief executive Joseph Jimenez.

Novartis acquired the blood diagnostics unit when it bought Chiron in 2006. The main point of that acquisition was to kick start their vaccine development programme. Novartis has since developed new influenza vaccines that can be produced faster than methods based on chicken eggs, for example.


Related Content

Novartis in the spotlight in mis-selling investigations

9 January 2014 Business

news image

Crackdown on pharma marketing continues with US and Japanese cases

$25bn-plus trade sharpens pharma giants’ focus

25 April 2014 Business

news image

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers